This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 11-14, 2026
Hynes Convention CenterBoston, MA

Dr. Dan Tardiff, PhD
Chief Scientific Officer at CAMP4 Therapeutics
Speaker

Profile

Dan Tardiff, PhD, is Chief Scientific Officer of CAMP4 where he oversees Platform and Discovery Teams to expand the scope of CAMP4’s discovery platform and advance the pipeline towards the clinic.

Prior to joining CAMP4, Dr. Tardiff led drug discovery projects and teams in both small biotech and large pharma across multiple drug modalities. Dr. Tardiff most recently led a team in the Rare Disease Research Unit at Pfizer exploring genetic medicines for rare neurological disorders. Prior to Pfizer, Dr. Tardiff was a scientific co-founder of Yumanity Therapeutics, where he helped build a platform to discover novel therapeutics for the treatment of neurodegenerative diseases. At Yumanity, he led teams from screening through translational research to discover new therapeutic targets and drug candidates, including a clinical-stage small molecule targeting stearoyl-CoA desaturase for the potential treatment of Parkinson’s disease.

Dr. Tardiff earned his BS in Biochemistry from Stonehill College and his PhD from Brandeis University. He completed his post-doctoral training at the Whitehead Institute for Biomedical Research with Dr. Susan Lindquist.

Agenda Sessions

  • Targeting Noncoding Regulatory RNAs with Antisense Oligonucleotides to Increase Gene Expression for the Potential Treatment of Haploinsufficient Diseases

    10:45am